Suzanne Thibodeaux

Medicine & Life Sciences

1. Blood Component Removal 100%
2. Immunotherapy 72%
3. Erythrocytes 63%
4. Chimeric Antigen Receptors 58%
5. T-Lymphocytes 54%
6. Regulatory T-Lymphocytes 52%
7. Toxoplasma 48%
8. Hematopoietic Stem Cells 47%
9. denileukin diftitox 42%
10. Sickle Hemoglobin 41%
11. Ovarian Neoplasms 39%
12. Equipment and Supplies Utilization 36%
13. Sickle Cell Anemia 32%
14. Blood Safety 30%
15. Donor Selection 28%
16. Coronavirus 27%
17. Immunity 27%
18. Proof of Concept Study 27%
19. Therapeutics 27%
20. Antithrombins 26%
21. Plasma Exchange 26%
22. Neoplasms 26%
23. Leukapheresis 25%
24. Tissue Donors 25%
25. Transfusion Medicine 25%
26. Communicable Diseases 24%
27. Parasites 23%
28. Cell- and Tissue-Based Therapy 23%
29. Pandemics 23%
30. Genetic Therapy 23%
31. Interleukin-17 23%
32. Workload 21%
33. Interferons 21%
34. Dendritic Cells 20%
35. Fibrinogen 20%
36. Sex Characteristics 20%
37. Patient Care 19%
38. Transfusion Reaction 19%
39. Virulence 18%
40. Theoretical Models 17%
41. Nitric Oxide 17%
42. Specific Gravity 17%
43. Blood Vessels 17%
44. Clinical Trials 17%
45. Blood Platelets 16%
46. Phosphotransferases 16%
47. Transplants 16%
48. Hemoglobin A 16%
49. Safety 15%
50. Adoptive Immunotherapy 15%